Literature DB >> 21046310

Detection of failure of bevacizumab treatment for malignant glioma based on urinary matrix metalloproteinase activity.

Shingo Takano1, Ryota Mashiko, Satoru Osuka, Eiichi Ishikawa, Osamu Ohneda, Akira Matsumura.   

Abstract

Although antiangiogenic treatment for malignant glioma using bevacizumab in combination with irinotecan chemotherapy has a promising effect on survival, the high incidence of increasing infiltrative tumors can be a problem in resistance to antiangiogenic therapy. In this study, we detected failure of bevacizumab treatment for malignant glioma through upregulation of metalloproteinase activity in the urine, as well as infiltrative tumors on MRI. In addition, MMP9 has been proved as a molecule that facilitates its infiltrative behavior in vivo in the brain animal model.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 21046310     DOI： 10.1007/s10014-010-0271-y

Source DB:  PubMed          Journal:  Brain Tumor Pathol        ISSN： 1433-7398            Impact factor:   3.298


  10 in total

1.  Direct effect of bevacizumab on glioblastoma cell lines in vitro.

Authors:  Thomas Simon; Bérénice Coquerel; Alexandre Petit; Yusra Kassim; Elise Demange; Didier Le Cerf; Valérie Perrot; Jean-Pierre Vannier
Journal:  Neuromolecular Med       Date:  2014-08-13       Impact factor: 3.843

2.  Association of matrix metalloproteinase 2 plasma level with response and survival in patients treated with bevacizumab for recurrent high-grade glioma.

Authors:  Emeline Tabouret; Françoise Boudouresque; Maryline Barrie; Mona Matta; Celine Boucard; Anderson Loundou; Antoine Carpentier; Marc Sanson; Philippe Metellus; Dominique Figarella-Branger; L'houcine Ouafik; Olivier Chinot
Journal:  Neuro Oncol       Date:  2013-12-09       Impact factor: 12.300

3.  Carboxyethylpyrroles: From Hypothesis to the Discovery of Biologically Active Natural Products.

Authors:  Robert G Salomon
Journal:  Chem Res Toxicol       Date:  2016-11-02       Impact factor: 3.739

4.  The effect of bevacizumab on human malignant melanoma cells with functional VEGF/VEGFR2 autocrine and intracrine signaling loops.

Authors:  Una Adamcic; Karolina Skowronski; Craig Peters; Jodi Morrison; Brenda L Coomber
Journal:  Neoplasia       Date:  2012-07       Impact factor: 5.715

5.  ProBDNF and its receptors are upregulated in glioma and inhibit the growth of glioma cells in vitro.

Authors:  Jing Xiong; Li Zhou; Miao Yang; Yoon Lim; Yu-hong Zhu; Deng-li Fu; Zhi-wei Li; Jin-hua Zhong; Zhi-cheng Xiao; Xin-Fu Zhou
Journal:  Neuro Oncol       Date:  2013-04-10       Impact factor: 12.300

6.  Neuroimaging classification of progression patterns in glioblastoma: a systematic review.

Authors:  Rory J Piper; Keerthi K Senthil; Jiun-Lin Yan; Stephen J Price
Journal:  J Neurooncol       Date:  2018-03-30       Impact factor: 4.130

7.  Plasmatic MMP9 released from tumor-infiltrating neutrophils is predictive for bevacizumab efficacy in glioblastoma patients: an AVAglio ancillary study.

Authors:  Carine Jiguet-Jiglaire; Sebastien Boissonneau; Emilie Denicolai; Victoria Hein; Romain Lasseur; Josep Garcia; Sylvie Romain; Romain Appay; Thomas Graillon; Warren Mason; Antoine F Carpentier; Alba A Brandes; L 'Houcine Ouafik; Wolfgang Wick; Ania Baaziz; Julien P Gigan; Rafael J Argüello; Dominique Figarella-Branger; Olivier Chinot; Emeline Tabouret
Journal:  Acta Neuropathol Commun       Date:  2022-01-03       Impact factor: 7.801

8.  Systematic analysis of potential targets of the curcumin analog pentagamavunon-1 (PGV-1) in overcoming resistance of glioblastoma cells to bevacizumab.

Authors:  Adam Hermawan; Herwandhani Putri
Journal:  Saudi Pharm J       Date:  2021-10-05       Impact factor: 4.330

Review 9.  Bevacizumab in Japanese patients with malignant glioma: from basic research to clinical trial.

Authors:  Shingo Takano; Eiichi Ishikawa; Kei Nakai; Masahide Matsuda; Tomohiko Masumoto; Tetsuya Yamamoto; Akira Matsumura
Journal:  Onco Targets Ther       Date:  2014-09-05       Impact factor: 4.147

Review 10.  Extracranial metastases of high-grade glioma: the clinical characteristics and mechanism.

Authors:  Qian Sun; Rui Xu; Hongbo Xu; Gengming Wang; Xueming Shen; Hao Jiang
Journal:  World J Surg Oncol       Date:  2017-10-06       Impact factor: 2.754
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.